Evidence map›Paper›PMID 37144543›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.

Peng Su, Yuchen Wu, Feng Xie, Qinghui Zheng, Long Chen, Zhuang Liu, Xuli Meng, Fangfang Zhou, Long Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Peng SuDepartment of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, 310014, P. R. China.
Yuchen WuDepartment of Clinical Medicine, The First School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, P. R. China.
Feng XieInstitutes of Biology and Medical Science, Soochow University, Suzhou, 215123, P. R. China.
Qinghui ZhengDepartment of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, 310014, P. R. China.
Long ChenCenter for Translational Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, Jiangsu, 215600, China.
Zhuang LiuInstitute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu, 215123, China.
Xuli MengDepartment of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, 310014, P. R. China.
Fangfang ZhouInstitutes of Biology and Medical Science, Soochow University, Suzhou, 215123, P. R. China.ORCID 0000-0003-1870-7584
Long ZhangDepartment of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, 310014, P. R. China.
Soochow University · CNZhejiang Provincial People's Hospital · CNWenzhou Medical University · CNZhejiang Cancer Hospital · CN

Funding

Chinese National Natural Science Funds 31870902Chinese National Natural Science Funds 31871405Chinese National Natural Science Funds 32070907Chinese National Natural Science Funds U20A20393Jiangsu Provincial Distinguished Young Scholars award BK20180043Key Project of University Natural Science Foundation of Jiangsu Province 19KJA550003Ministry of Science and Technology of China 2021YFA101000Ministry of Science and Technology of China 2022YFA1105200National Science Fund for Distinguished Young Scholars 31925013National Science Fund for Distinguished Young Scholars 32125016Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX17_2036Priority Academic Program Development of Jiangsu Higher Education InstitutionsZhejiang Natural Science Fund LD19C070001Zhejiang Provincial Science and Technology Innovation Program (New Young Talent Program) for College Students 2020R413007
6 · The paper itself

Abstract

The 2019 novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing, and has necessitated scientific efforts in disease diagnosis, treatment, and prevention. Interestingly, extracellular vesicles (EVs) have been crucial in these developments. EVs are a collection of various nanovesicles which are delimited by a lipid bilayer. They are enriched in proteins, nucleic acids, lipids, and metabolites, and naturally released from different cells. Their natural material transport properties, inherent long-term recycling ability, excellent biocompatibility, editable targeting, and inheritance of parental cell properties make EVs one of the most promising next-generation drug delivery nanocarriers and active biologics. During the COVID-19 pandemic, many efforts have been made to exploit the payload of natural EVs for the treatment of COVID-19. Furthermore, strategies that use engineered EVs to manufacture vaccines and neutralization traps have produced excellent efficacy in animal experiments and clinical trials. Here, the recent literature on the application of EVs in COVID-19 diagnosis, treatment, damage repair, and prevention is reviewed. And the therapeutic value, application strategies, safety, and biotoxicity in the production and clinical applications of EV agents for COVID-19 treatment, as well as inspiration for using EVs to block and eliminate novel viruses are discussed.

Indexed as

COVID-19Extracellular VesiclesAnimalsCOVID-19 Drug TreatmentCOVID-19 TestingHumansPandemicsSARS-CoV-2coronavirus disease 2019diagnosisdrug deliveryextracellular vesiclesneutralization traps

Identifiers

PMID37144543
PMCPMC10323633
OpenAlexW4372295597

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.